The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Open accessAbstract
BACKGROUND: In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been associated with a lower risk of coronary heart disease events. However, whether raising HDL cholesterol levels therapeutically reduces cardiovascular risk remains uncertain. Inhibition of cholesteryl ester transfer protein (CETP) raises HDL cholesterol levels and might therefore improve cardiovascular outcomes. METHODS: We randomly assigned 15,871 patients who had had a recent acute coronary syndrome to receive the CETP inhibitor dalcetrapib, at a dose of 600 mg daily, or placebo, in addition to the best available evidence-based care. The primary efficacy end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation. RESULTS: At the time of randomization, the mean HDL cholesterol level was 42 mg per deciliter (1.1 mmol per liter), and the mean low-density lipoprotein (LDL) cholesterol level was 76 mg per deciliter (2.0 mmol per liter). Over the course of the trial, HDL cholesterol levels increased from baseline by 4 to 11% in the placebo group and by 31 to 40% in the dalcetrapib group. Dalcetrapib had a minimal effect on LDL cholesterol levels. Patients were followed for a median of 31 months. At a prespecified interim analysis that included 1135 primary end-point events (71% of the projected total number), the independent data and safety monitoring board recommended termination of the trial for futility. As compared with placebo, dalcetrapib did not alter the risk of the primary end point (cumulative event rate, 8.0% and 8.3%, respectively; hazard ratio with dalcetrapib, 1.04; 95% confidence interval, 0.93 to 1.16; P=0.52) and did not have a significant effect on any component of the primary end point or total mortality. The median C-reactive protein level was 0.2 mg per liter higher and the mean systolic blood pressure was 0.6 mm Hg higher with dalcetrapib as compared with placebo (P<0.001 for both comparisons). CONCLUSIONS: In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events. (Funded by F. Hoffmann-La Roche; dal-OUTCOMES ClinicalTrials.gov number, NCT00658515.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last factor probably also contributed to the rise in LDL cholesterol observed in the placebo group, in the on-treatment analysis in the alirocumab group, and in previous trials involving patients who had an acute coronary syndrome. 5,21”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unfortunately, early generations of CETP inhibitors were either associated with off-target adverse effects with safety concerns, or had no significant or only modest LDL-C lowering and thus failed to demonstrate cardiovascular benefit, leading to a loss of enthusiasm in this drug class [[7], [8], [9], [10]].”
From Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials (2025) · cites this paper as [8]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events [63-67].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Anacetrapib reduced major coronary events by 9% over a median of 4.1 years [64].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“More recently, the REVEAL study investigated anacetrapib in > 30 000 patients with atherosclerotic vascular disease and resulted in a lower incidence of MACE compared with placebo after 4 years, with no safety concerns [64].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [64]
In the citing paper
“Furthermore, in patients who had experienced a recent ACS, the CETP inhibitor dalcetrapib did not reduce the risk of recurrent CV events. 362”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [362]
In the citing paper
“Furthermore, in patients who had experienced a recent ACS, the CETP inhibitor dalcetrapib did not reduce the risk of recurrent CV events.362”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [362]
In the citing paper
“Colocalization, which is a statistical approach that quantifies the extent to which two traits share the same underlying causal variant, and thus can be used to infer vertical pleiotropy 83-85 , can be used to test for such bias 86 , but can suffer from issues of lack of power and/or availability of suitable data from relevant tissues.”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [85]
In the citing paper
“However, three out of four prospective studies with CETP inhibitors had to be terminated due to increased mortality in the treatment group or due to futility (Table 3).”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [107]
In the citing paper
“outcome trials that have targeted HDL-C pharmacologically and have included patients with low HDL-C at baseline, have not demonstrated reduced CVD risk despite appreciable increases in HDL-C.5-10”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [6]
In the citing paper
“In contrast, recent studies have failed to demonstrate that high HDL-C acquired naturally or pharmacologically, is associated with reduced CVD risk.5-11,18”
From Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor?: New Insights From the Framingham Offspring Study (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Flagged first, then by citations
2 of the 35 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 1,004
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis
Yu, X.-H., Zhang, D., Zheng, X., & Tang, C. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.12.002 · Cited by 222
Varbo, A., Freiberg, J. J., & Nordestgaard, B. G. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.234146 · Cited by 209
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis
Semb, A. G., Ikdahl, E., Wibetoe, G., Crowson, C. S., & Rollefstad, S. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0428-y · Cited by 221
Ronsein, G. E., Pamir, N., von Haller, P. D., Kim, D. S., Oda, M. N., Jarvik, G. P., Vaisar, T., & Heinecke, J. W. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.10.017 · Cited by 225
High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans
Bowe, B., Xie, Y., Xian, H., Balasubramanian, S., Zayed, M. A., & Al-Aly, Z. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00730116 · Cited by 213
Xiao, C., Dash, S., Morgantini, C., Hegele, R. A., & Lewis, G. F. (2016) · Diabetes · doi:10.2337/db16-0046 · Cited by 212
SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis
Linton, M. F., Tao, H., Linton, E. F., & Yancey, P. G. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.02.001 · Cited by 221
Hemingway, H., Asselbergs, F. W., Danesh, J., Dobson, R., Maniadakis, N., Maggioni, A. P., van Thiel, G. J. M. W., Cronin, M., Brobert, G., Vardas, P. E., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx487 · Cited by 218
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., Reist, C., Im, K., Bohula, E. A., Isaza, D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.077 · Cited by 205
Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
Banach, M., Stulc, T., Dent, R., & Toth, P. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.075 · Cited by 197
Novel methodologies for biomarker discovery in atherosclerosis
Hoefer, I. E., Steffens, S., Ala‐Korpela, M., Bäck, M., Badimón, L., Bochaton‐Piallat, M., Boulanger, C. M., Caligiuri, G., Dimmeler, S., Egido, J., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv236 · Cited by 206
Coronary Atherosclerotic Plaque Regression
Dawson, L. P., Lum, M., Nerlekar, N., Nicholls, S. J., & Layland, J. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.10.035 · Cited by 209
Self-citationZhao, Q., Chen, Y., Wang, J., & Small, D. S. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyz142 · Cited by 188
Myocardial Infarction—From Atherosclerosis to Thrombosis
Palasubramaniam, J., Wang, X., & Peter, K. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312578 · Cited by 208
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Dhindsa, D. S., Sandesara, P. B., Shapiro, M. D., & Wong, N. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00088 · Cited by 208
A Mendelian randomization study of the effects of blood lipids on breast cancer risk
Nowak, C., & Ärnlöv, J. (2018) · Nature Communications · doi:10.1038/s41467-018-06467-9 · Cited by 193
Gibson, C. M., Korjian, S., Tricoci, P., Daaboul, Y., Yee, M., Jain, P., Alexander, J. H., Steg, P. G., Lincoff, A. M., Kastelein, J. J. P., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.025687 · Cited by 193
Cholesterol Crystals and Inflammation
Grebe, A., & Latz, E. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-012-0313-z · Cited by 192
Anabolic–androgenic steroids: How do they work and what are the risks?
Bond, P., Smit, D. L., & de Ronde, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1059473 · Cited by 235
Elam, M. B., Ginsberg, H. N., Lovato, L. C., Corson, M., Largay, J., Leiter, L. A., Lopez, C., O’Connor, P. J., Sweeney, M. E., Weiss, D., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.4828 · Cited by 185
Self-citationHolmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184
Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor
Tenenbaum, A., Klempfner, R., & Fisman, E. Z. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0159-y · Cited by 193
Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease
Budoff, M. J. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.04.004 · Cited by 186
Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
Tardif, J., Rhéaume, É., Perreault, L. L., Grégoire, J. C., Zada, Y. F., Asselin, G., Provost, S., Barhdadi, A., Rhainds, D., L’Allier, P. L., et al. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000663 · Cited by 183
Self-citationHDL and cognition in neurodegenerative disorders
Hottman, D. A., Chernick, D., Cheng, S., Wang, Z., & Li, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.015 · Cited by 188
Annema, W., & von Eckardstein, A. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-1025 · Cited by 185
APOA1: a Protein with Multiple Therapeutic Functions
Cochran, B. J., Ong, K. L., Manandhar, B., & Rye, K. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00906-7 · Cited by 185
Boekholdt, S. M., Arsenault, B. J., Hovingh, G. K., Mora, S., Pedersen, T. R., LaRosa, J. C., Welch, K. M. A., Amarenco, P., DeMicco, D. A., Tonkin, A. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002670 · Cited by 196
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Lipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Nicholls, S. J., Ditmarsch, M., Kastelein, J. J. P., Rigby, S. P., Kling, D. F., Curcio, D. L., Alp, N. J., & Davidson, M. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01936-7 · Cited by 175
Self-citationResidual macrovascular risk in 2013: what have we learned?
(R3i), F. T. R. R. R. I., Fruchart, J., Davignon, J., Hermans, M. P., Al-Rubeaan, K. A., Amarenco, P., Assmann, G., Barter, P. J., Betteridge, J. D., Bruckert, É., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-26 · Cited by 174
Self-citationHigh-Density Lipoprotein Cholesterol and Mortality
Hamer, M., O’Donovan, G., & Stamatakis, E. A. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310587 · Cited by 171
Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
Lorber, D. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s61438 · Cited by 171
Riwanto, M., & Landmesser, U. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r037762 · Cited by 174
High-Density Lipoprotein and Atherosclerosis Regression
Feig, J. E., Hewing, B., Smith, J. D., Hazen, S. L., & Fisher, E. A. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.300760 · Cited by 172
Kazé, A. D., Santhanam, P., Musani, S. K., Ahima, R. S., & Echouffo-Tcheugui, J. B. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.016947 · Cited by 177
Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study
Nazarzadeh, M., Pinho-Gomes, A.-C., Bidel, Z., Dehghan, A., Canoy, D., Hassaine, A., Ayala Solares, J. R., Salimi-Khorshidi, G., Smith, G. D., Otto, C. M., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa070 · Cited by 163
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Arvanitis, M., & Lowenstein, C. J. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202306200 · Cited by 174
2017 Taiwan lipid guidelines for high risk patients
Li, Y., Ueng, K., Jeng, J., Charng, M., Lin, T., Chien, K., Wang, C., Chao, T., Liu, P., Su, C., et al. (2017) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.11.013 · Cited by 166
Burgess, S., & Smith, G. D. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.03.042 · Cited by 155
Cyclodextrin Protects Podocytes in Diabetic Kidney Disease
Merscher, S., Guzman, J., Pedigo, C. E., Lehto, M. J., Aguillon, R. A., Mendez, A. J., Lassenius, M. I., Forsblom, C. M., Yoo, T., Villarreal, R., et al. (2013) · Diabetes · doi:10.2337/db13-0399 · Cited by 154
Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk
Zewinger, S., Drechsler, C., Kleber, M. E., Dressel, A., Riffel, J., Triem, S., Lehmann, M., Kopecky, C., Säemann, M. D., Lepper, P. M., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv352 · Cited by 151
Noninvasive Molecular Imaging of Disease Activity in Atherosclerosis
Dweck, M. R., Aïkawa, E., Newby, D. E., Tarkin, J. M., Rudd, J. H. F., Narula, J., & Fayad, Z. A. (2016) · Circulation Research · doi:10.1161/circresaha.116.307971 · Cited by 148
Hirata, A., Sugiyama, D., Watanabe, M., Tamakoshi, A., Iso, H., Kotani, K., Kiyama, M., Yamada, M., Ishikawa, S., Murakami, Y., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.014 · Cited by 150
High-Density Lipoprotein Function and Dysfunction in Health and Disease
Chiesa, S. T., & Charakida, M. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-06846-w · Cited by 155
Zhang, T., Chen, J., Tang, X., Luo, Q., Xu, D., & Yu, B. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1170-9 · Cited by 163
HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy
Linton, M. F., Yancey, P. G., Tao, H., & Davies, S. S. (2023) · Circulation Research · doi:10.1161/circresaha.123.321563 · Cited by 159
HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology
Rosenson, R. S., Brewer, H. B., Barter, P. J., Björkegren, J., Chapman, M. J., Gaudet, D., Kim, D. S., Niesor, E. J., Rye, K., Sacks, F. M., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.115 · Cited by 149
Self-citationFruchart, J.-C. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0602-y · Cited by 141
Hewing, B., Parathath, S., Barrett, T. J., Chung, W. K. K., Astudillo, Y., Hamada, T., Ramkhelawon, B., Tallant, T. C., Yusufishaq, M., DiDonato, J., et al. (2014) · Arteriosclerosis, Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.303044 · Cited by 147
Cholesterol Efflux and Reverse Cholesterol Transport
Favari, E., Chroni, A., Tietge, U. J. F., Zanotti, I., Escolá‐Gil, J. C., & Bernini, F. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_4 · Cited by 148
Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events
Armitage, J., Holmes, M. V., & Preiss, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.10.072 · Cited by 140
Nazir, S., Jankowski, V., Bender, G., Zewinger, S., Rye, K.-A., & van der Vorst, E. P. C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.006 · Cited by 140
Fruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Self-citationZhong, G., Huang, S.-Q., Peng, Y., Wan, L., Wu, Y., Hu, T., Hu, J., & Hao, F. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320914756 · Cited by 141
Averna, M. R., Banach, M., Bruckert, É., Drexel, H., Farnier, M., Gaiță, D. I., Magni, P., März, W., Masana, L., Silva, A. M. E., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.039 · Cited by 143
Lipoproteins and lipoprotein mimetics for imaging and drug delivery
Thaxton, C. S., Rink, J. S., Naha, P. C., & Cormode, D. P. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.020 · Cited by 142
Metabolic profiling of alcohol consumption in 9778 young adults
Würtz, P., Cook, S., Wang, Q., Tiainen, M., Tynkkynen, T., Kangas, A. J., Soininen, P., Laitinen, J. H., Viikari, J. S. A., Kähönen, M. A. P., et al. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw175 · Cited by 139
Evaluating Evidence of Mechanisms in Medicine
Parkkinen, V., Wallmann, C., Wilde, M., Clarke, B., Illari, P. K., Kelly, M. P., Norell, C. H., Federica Russo, B., Shaw, B., & Williamson, J. (2018) · SpringerBriefs in philosophy · doi:10.1007/978-3-319-94610-8 · Cited by 164
Wilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2019) · Circulation · doi:10.1161/cir.0000000000000626 · Cited by 137
Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials
Koch, C. A., Kjeldsen, E. W., & Frikke‐Schmidt, R. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad211 · Cited by 142
Jahagirdar, R., Zhang, H., Azhar, S., Tobin, J., Attwell, S., Yu, R., Wu, J., McLure, K. G., Hansen, H. C., Wagner, G. S., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.06.008 · Cited by 134
HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role
Casula, M., Colpani, O., Xie, S., Catapano, A. L., & Baragetti, A. (2021) · Cells · doi:10.3390/cells10081869 · Cited by 149
Trinder, M., Walley, K. R., Boyd, J. H., & Brunham, L. R. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313381 · Cited by 126
van der Made, S. M., Plat, J., & Mensink, R. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118393 · Cited by 131
Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm
Harrison, S. C., Holmes, M. V., Burgess, S., Asselbergs, F. W., Jones, G. T., Baas, A. F., Hof, F. N. G. V. ’., de Bakker, P. I. W., Blankensteijn, J. D., Powell, J. T., et al. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.4293 · Cited by 131
Proof That Lower Is Better — LDL Cholesterol and IMPROVE-IT
Jarcho, J. A., & Keaney, J. F. (2015) · New England Journal of Medicine · doi:10.1056/nejme1507041 · Cited by 131
Novel anti-inflammatory therapies for the treatment of atherosclerosis
Khan, R., Spagnoli, V., Tardif, J., & L’Allier, P. L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.04.783 · Cited by 130
Self-citationImaging atherosclerosis with positron emission tomography
Joseph, P., & Tawakol, A. A. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw147 · Cited by 131
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Rosenzweig, J. L., Bakris, G. L., Berglund, L., Hivert, M., Horton, E. S., Kalyani, R. R., Murad, M. H., & Vergès, B. L. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01338 · Cited by 133
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality
Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., Grammer, T. B., Ritsch, A., Mons, U., Holleczek, B., Goliasch, G., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht343 · Cited by 123
The Genetic Basis of Metabolic Disease
Barroso, I., & McCarthy, M. I. (2019) · Cell · doi:10.1016/j.cell.2019.02.024 · Cited by 129
Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview
Suh, S. H., & Kim, S. W. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0067 · Cited by 138
Stabilization of atherosclerotic plaques: an update
Ylä‐Herttuala, S., Bentzon, J. F., Daemen, M. J. A. P., Falk, E., García‐García, H. M., Herrmann, J., Hoefer, I. E., Jauhiainen, S., Jukema, J. W., Krams, R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht301 · Cited by 127
HDL in Children with CKD Promotes Endothelial Dysfunction and an Abnormal Vascular Phenotype
Shroff, R. C., Speer, T., Colin, S., Charakida, M., Zewinger, S., Staels, B., Chinetti, G., Hettrich, I., Rohrer, L., O’Neill, F., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013111212 · Cited by 122
From High-Density Lipoprotein Cholesterol to Measurements of Function
Sacks, F. M., & Jensen, M. K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.307025 · Cited by 121
Biological Consequences of Dysfunctional HDL
Pirillo, A., Catapano, A. L., & Norata, G. D. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180530110543 · Cited by 122
Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence
Wang, Q., Würtz, P., Auro, K., Morin-Papunen, L., Kangas, A. J., Soininen, P., Tiainen, M., Tynkkynen, T., Joensuu, A., Havulinna, A. S., et al. (2016) · International Journal of Epidemiology · doi:10.1093/ije/dyw147 · Cited by 117
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Lipid biology of the podocyte—new perspectives offer new opportunities
Fornoni, A., Merscher, S., & Kopp, J. B. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.87 · Cited by 119
Tricoci, P., D’Andrea, D. M., Gurbel, P. A., Yao, Z., Cuchel, M., Winston, B., Schott, R. J., Weiss, R., Blazing, M. A., Cannon, L., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002171 · Cited by 119
Kohan, A. B. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000136 · Cited by 116
Nicholls, S. J., Ruotolo, G., Brewer, H. B., Kane, J. P., Wang, M.-D., Krueger, K. A., Adelman, S. J., Nissen, S. E., & Rader, D. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.013 · Cited by 119
Self-citationHDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
DiDonato, J. A., Huang, Y. R., Aulak, K. S., Even‐Or, O., Gerstenecker, G. S., Gogonea, V., Wu, Y., Fox, P. L., Tang, W. H. W., Plow, E. F., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002624 · Cited by 119
Hyperuricemia is associated with impaired intestinal permeability in mice
Xu, D., Lv, Q., Wang, X., Cui, X., Zhao, P., Yang, X., Liu, X., Yang, W. Q., Yang, G., Wang, G., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00151.2019 · Cited by 110
Nicholls, S. J., Puri, R., Wolski, K., Ballantyne, C. M., Barter, P. J., Brewer, H. B., Kastelein, J. J. P., Hu, B., Uno, K., Kataoka, Y., et al. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0146-z · Cited by 107
Self-citationThe Changing Face of HDL and the Best Way to Measure It
Karathanasis, S. K., Freeman, L. A., Gordon, S. M., & Remaley, A. T. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.257725 · Cited by 112
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 108
Kratzer, A., Giral, H., & Landmesser, U. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu139 · Cited by 112
Association of Air Pollution Exposures With High-Density Lipoprotein Cholesterol and Particle Number
Bell, G. A., Mora, S., Greenland, P., Tsai, M. Y., Gill, E., & Kaufman, J. D. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308193 · Cited by 110
High density lipoprotein cholesterol and cancer: Marker or causative?
Pirro, M., Ricciuti, B., Rader, D. J., Catapano, A. L., Sahebkar, A., & Banach, M. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2018.06.001 · Cited by 107
Novel metabolic biomarkers of cardiovascular disease
Jensen, M. K., Bertoia, M. L., Cahill, L. E., Agarwal, I., Rimm, E. B., & Mukamal, K. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.155 · Cited by 109
Guo, Y., Yuan, W., Yu, B., Kuai, R., Hu, W., Morin, E. E., Garcia-Barrio, M. T., Zhang, J., Moon, J. J., Schwendeman, A. A., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.12.021 · Cited by 107
HDL Triglycerides: A New Marker of Metabolic and Cardiovascular Risk
Girona, J., Amigó, N., Ibarretxe, D., Plana, N., Rodríguez-Borjabad, C., Heras, M., Ferré, R., Gil, M., Correig, X., & Masana, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133151 · Cited by 107
Trinder, M., Wang, Y., Madsen, C. M., Ponomarev, T., Bohunek, L., Daisely, B. A., Kong, H. J., Blauw, L. L., Nordestgaard, B. G., Tybjærg‐Hansen, A., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.048568 · Cited by 110
Metadata
- Authors
- Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., Leitersdorf, E., McMurray, J. J. V., Mundl, H., Nicholls, S. J., Shah, P. K., Tardif, J.-C., & Wright, R. S.
- Affiliations
- Denver VA Medical Center (US)
- Linköping University (SE)
- F. Hoffmann-La Roche AG (CH)
- Baylor College of Medicine (US)
- University of Zurich (CH)
- Oslo University Hospital (NO)
- St. Michael's Hospital (CA)
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-11-29
- Volume
- 367
- Issue
- 22
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118825330
- Cited by
- 2,022
- References
- 35
- Citations by year
- 2026: 66 · 2025: 82 · 2024: 81 · 2023: 89 · 2022: 103 · 2021: 128 · 2020: 109 · 2019: 141 · 2018: 164 · 2017: 195 · 2016: 222 · 2015: 244 · 2014: 191 · 2013: 190 · 2012: 7
- FWCI
- 206.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- F. Hoffmann-La Roche
- CSL Behring
- Amarin Corporation
- Anthera
- Kowa Company
- Servier
- Esperion Therapeutics
- Genentech
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- dalcetrapib, cholesteryl ester transfer protein inhibition, HDL cholesterol, acute coronary syndrome, cardiovascular risk, futility, LDL cholesterol, C-reactive protein, systolic blood pressure, myocardial infarction, ischemic stroke, unstable angina, cardiovascular mortality, lipid-lowering therapy
- MeSH terms
- Aged, Amides, Anticholesteremic Agents, Apolipoproteins, Blood Pressure, C-Reactive Protein, Cardiovascular Diseases, Esters, Female, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk, Sulfhydryl Compounds, Triglycerides, Biomarkers, Cholesterol Ester Transfer Proteins, Acute Coronary Syndrome, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
